Korean startup KLMBio accelerates global expansion in bone graft market

South Korea-based KLMBio, a manufacturer and exporter of human tissue-based medical devices, is accelerating its global business expansion by strengthening its high-value tissue-based product portfolio to target the rapidly growing global bone graft market.

The global bone graft market is a high-growth medical device sector, driven by steadily increasing usage in orthopedic surgery, spinal procedures, and dental implants. The market is projected to reach approximately $6.66 billion by 2032. In particular, human tissue-based products continue to gain market preference and profitability due to their limited supply and consistently strong demand.

KLMBio is implementing a global marketing strategy under the slogan “Korea’s Specialized Manufacturer of Tissue-Based Therapeutic Materials.” The company has obtained key regulatory certifications, including AATB and FDA approvals in the United States, KFDA approval in Korea, and CTO certification in Canada. Leveraging these credentials, the startup is expanding its global presence across North America, Asia, and the Middle East. 

KLMBio aims to increase its overseas sales ratio from the current 10% to a balanced 50:50 split between domestic and international markets after 2026.

Looking ahead, KLMBio plans to allocate approximately 40% of its total investment toward expanding production capacity, including the construction of a second manufacturing facility with cleanrooms and additional sterilization, freeze-drying, and packaging equipment. The company will also accelerate the commercialisation of high-value products such as DBM Fiber, Dental Plug, and Amnion, strengthen regulatory capabilities through GMP and AATB certifications, and expand its specialized workforce to further enhance global competitiveness.